{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:00:05Z","timestamp":1790103605940,"version":"4.0.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The basal forebrain (BF) is a site of early tau pathology deposition, and BF cholinergic neurons selectively degenerate in patients with Alzheimer\u2019s disease (AD). PET imaging of AD pathology has helped to establish the relationships between early tau in the medial temporal lobe (MTL), amyloid (A\u03b2) pathology, brain structure and cognition, but it is not clear if PET imaging can be used to similarly characterize early tau pathology in the BF. Here we aim to test the feasibility of measuring tau pathology in the BF in unimpaired older adults with two PET tracers, [\n                    <jats:sup>18<\/jats:sup>\n                    F]flortaucipir (FTP) and [\n                    <jats:sup>18<\/jats:sup>\n                    F]MK6240, that have unique properties including distinct off-target signal (OTS) patterns. 1397 unimpaired older adult participants with either FTP (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009509; Berkeley Aging Cohort Study, ADNI) or MK6240 (\n                    <jats:italic>n\u2009<\/jats:italic>\n                    =\u2009888; POINTER Imaging study) scans were included and used to quantify tau-PET signal in three ROI categories: the BF, typical temporal tau-PET ROIs (entorhinal cortex [ERC], temporal MetaROI) and OTS ROIs that are adjacent to the BF (thalamus, pallidum). BF and temporal tau burden were associated with global A\u03b2 burden, but OTS was not. BF and MTL tau showed similar associations with age, BF volume, hippocampal volume and multi-domain cognition. Associations were consistent in both FTP and MK6240 cohorts. MTL tau was negatively correlated with BF volume in whole-brain morphometry analyses. Our findings suggest that it is feasible to use PET to measure tau signal in the BF in unimpaired older adults.\n                  <\/jats:p>","DOI":"10.1038\/s41386-026-02564-2","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:22:23Z","timestamp":1790094143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Measuring in-vivo tau pathology in the basal forebrain with PET imaging"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2036-3496","authenticated-orcid":false,"given":"Theresa M.","family":"Harrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor A.","family":"Chadwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel J.","family":"Grothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne L.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4458-113X","authenticated-orcid":false,"given":"William J.","family":"Jagust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"2564_CR1","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1002\/cne.23415","volume":"521","author":"M-M Mesulam","year":"2013","unstructured":"Mesulam M-M. Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer\u2019s disease. J Comp Neurol. 2013;521:4124\u201344.","journal-title":"J Comp Neurol"},{"key":"2564_CR2","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1126\/science.7058341","volume":"215","author":"P Whitehouse","year":"1982","unstructured":"Whitehouse P, Price D, Struble R, Clark A, Coyle J, DeLong MR. Alzheimer\u2019s Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain. Science. 1982;215:1237\u20139.","journal-title":"Science"},{"key":"2564_CR3","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/ana.20100","volume":"55","author":"M Mesulam","year":"2004","unstructured":"Mesulam M, Shaw P, Mash D, Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol. 2004;55:815\u201328.","journal-title":"Ann Neurol"},{"key":"2564_CR4","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","volume":"2","author":"P Davies","year":"1976","unstructured":"Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer\u2019s disease. Lancet Lond Engl. 1976;2:1403.","journal-title":"Lancet Lond Engl"},{"key":"2564_CR5","first-page":"136","volume":"50","author":"SL Rogers","year":"1998","unstructured":"Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer\u2019s disease. Donepezil Study Group Neurol. 1998;50:136\u201345.","journal-title":"Donepezil Study Group Neurol"},{"key":"2564_CR6","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","volume":"318","author":"M R\u00f6sler","year":"1999","unstructured":"R\u00f6sler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease: international randomised controlled trial. BMJ. 1999;318:633\u20138.","journal-title":"BMJ"},{"key":"2564_CR7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/bpa.12289","volume":"26","author":"K Stratmann","year":"2016","unstructured":"Stratmann K, Heinsen H, Korf HW, Del Turco D, Ghebremedhin E, Seidel K, et al. Precortical Phase of Alzheimer\u2019s Disease (AD)-Related Tau Cytoskeletal Pathology. Brain Pathol. 2016;26:371\u201386.","journal-title":"Brain Pathol"},{"key":"2564_CR8","doi-asserted-by":"crossref","unstructured":"Maass A, Lockhart SN, Harrison TM, Bell RK, Mellinger T, Swinnerton K, et al. Entorhinal tau pathology, episodic memory decline, and neurodegeneration in aging. J Neurosci. 2018;38(3):530\u2013543.","DOI":"10.1523\/JNEUROSCI.2028-17.2017"},{"key":"2564_CR9","first-page":"ana.25395","volume":"85","author":"RA Sperling","year":"2018","unstructured":"Sperling RA, Mormino EC, Schultz AP, Betensky RA, Papp KV, Amariglio RE, et al. The impact of A\u03b2 and tau on prospective cognitive decline in older individuals. Ann Neurol. 2018;85:ana.25395.","journal-title":"Ann Neurol"},{"key":"2564_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3233\/JAD-170945","volume":"62","author":"L Xie","year":"2018","unstructured":"Xie L, Das SR, Wisse LEM, Ittyerah R, Yushkevich PA, Wolk DA. Early Tau Burden Correlates with Higher Rate of Atrophy in Transentorhinal Cortex. J Alzheimers Dis JAD. 2018;62:85\u201392.","journal-title":"J Alzheimers Dis JAD"},{"key":"2564_CR11","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1093\/brain\/awab114","volume":"144","author":"D Berron","year":"2021","unstructured":"Berron D, Vogel JW, Insel PS, Pereira JB, Xie L, Wisse LEM, et al. Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. Brain. 2021;144:2771\u201383.","journal-title":"Brain"},{"key":"2564_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neurobiolaging.2018.01.024","volume":"66","author":"SR Das","year":"2018","unstructured":"Das SR, Xie L, Wisse LEM, Ittyerah R, Tustison NJ, Dickerson BC, et al. Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake. Neurobiol Aging. 2018;66:49\u201358.","journal-title":"Neurobiol Aging"},{"key":"2564_CR13","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jalz.2019.05.009","volume":"15","author":"SR Das","year":"2019","unstructured":"Das SR, Xie L, Wisse LEM, Vergnet N, Ittyerah R, Cui S, et al. In vivo measures of tau burden are associated with atrophy in early Braak stage medial temporal lobe regions in amyloid-negative individuals. Alzheimers Dement. 2019;15:1286\u201395.","journal-title":"Alzheimers Dement"},{"key":"2564_CR14","doi-asserted-by":"crossref","unstructured":"Baker SL, Harrison TM, Maass A, Joie RL, Jagust WJ. Effect of off-target binding on 18F-flortaucipir variability in healthy controls across the life span. J Nucl Med. 2019;60(10):1444\u20131451","DOI":"10.2967\/jnumed.118.224113"},{"key":"2564_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2022.119761","volume":"265","author":"TM Harrison","year":"2023","unstructured":"Harrison TM, Ward TJ, Murphy A, Baker SL, Dominguez PA, Koeppe R, et al. Optimizing quantification of MK6240 tau PET in unimpaired older adults. NeuroImage. 2023;265:119761.","journal-title":"NeuroImage"},{"key":"2564_CR16","doi-asserted-by":"crossref","unstructured":"Smith R, Strandberg O, Leuzy A, Betthauser TJ, Johnson SC, Pereira JB, et al. Sex differences in off-target binding using tau positron emission tomography. NeuroImage Clin. 2021;31:102708","DOI":"10.1016\/j.nicl.2021.102708"},{"key":"2564_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1162\/imag_a_00135","volume":"2","author":"A McVea","year":"2024","unstructured":"McVea A, DiFilippo A, McLachlan MJ, Zammit MD, Bendlin B, Johnson SC, et al. Evaluating the effect of extra-cerebral off-target binding in [F-18]MK6240 PET scans in early-stage Alzheimer\u2019s disease. Imaging Neurosci. 2024;2:1\u201320.","journal-title":"Imaging Neurosci"},{"key":"2564_CR18","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/hbm.24417","volume":"40","author":"HJ Fritz","year":"2019","unstructured":"Fritz HJ, Ray N, Dyrba M, Sorg C, Teipel S, Grothe MJ. The corticotopic organization of the human basal forebrain as revealed by regionally selective functional connectivity profiles. Hum Brain Mapp. 2019;40:868.","journal-title":"Hum Brain Mapp"},{"key":"2564_CR19","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/0306-4522(83)90108-2","volume":"10","author":"MM Mesulam","year":"1983","unstructured":"Mesulam MM, Mufson EJ, Wainer BH, Levey AI. Central cholinergic pathways in the rat: An overview based on an alternative nomenclature (Ch1\u2013Ch6). Neuroscience. 1983;10:1185\u2013201.","journal-title":"Neuroscience"},{"key":"2564_CR20","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.neuron.2016.09.006","volume":"91","author":"E Ballinger","year":"2016","unstructured":"Ballinger E, Ananth M, Talmage DA, Role L. Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline. Neuron. 2016;91:1199\u2013218.","journal-title":"Neuron"},{"key":"2564_CR21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209626","volume":"103","author":"Y Xia","year":"2024","unstructured":"Xia Y, Dore V, Fripp J, Bourgeat P, Laws SM, Fowler CJ, et al. Association of Basal Forebrain Atrophy With Cognitive Decline in Early Alzheimer Disease. Neurology. 2024;103:e209626.","journal-title":"Neurology"},{"key":"2564_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.neuropsychologia.2013.11.002","volume":"53","author":"D Wolf","year":"2014","unstructured":"Wolf D, Grothe M, Fischer FU, Heinsen H, Kilimann I, Teipel S, et al. Association of basal forebrain volumes and cognition in normal aging. Neuropsychologia. 2014;53:54\u201363.","journal-title":"Neuropsychologia"},{"key":"2564_CR23","doi-asserted-by":"publisher","unstructured":"Harrison TM, Ward T, Taggett J, Maillard P, Lockhart SN, Jung Y, et al. The POINTER Imaging baseline cohort: Associations between multimodal neuroimaging biomarkers, cardiovascular health, and cognition. Alzheimers Dement J Alzheimers Assoc. 2024. https:\/\/doi.org\/10.1002\/alz.14399.","DOI":"10.1002\/alz.14399"},{"key":"2564_CR24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI): Clinical characterization. Neurology. 2010;74:201\u20139.","journal-title":"Neurology"},{"key":"2564_CR25","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s11682-012-9186-z","volume":"6","author":"PK Crane","year":"2012","unstructured":"Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, et al.for the lzheimer\u2019s Disease Neuroimaging Initiative Development and assessment of a composite score for memory in the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav. 2012;6:502\u201316.","journal-title":"Brain Imaging Behav"},{"key":"2564_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11682-012-9176-1","volume":"6","author":"LE Gibbons","year":"2012","unstructured":"Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, et al.for the Alzheimer\u2019s Disease Neuroimaging Initiative. A composite score for executive functioning, validated in Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav. 2012;6:517\u201327.","journal-title":"Brain Imaging Behav"},{"key":"2564_CR27","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.jalz.2017.01.018","volume":"13","author":"EC Mormino","year":"2017","unstructured":"Mormino EC, Papp KV, Rentz DM, Donohue MC, Amariglio R, Quiroz YT, et al. Early and late change on the preclinical Alzheimer\u2019s cognitive composite in clinically normal older individuals with elevated amyloid \u03b2. Alzheimers Dement. 2017;13:1004\u201312.","journal-title":"Alzheimers Dement"},{"key":"2564_CR28","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/alz.13365","volume":"20","author":"LD Baker","year":"2024","unstructured":"Baker LD, Snyder HM, Espeland MA, Whitmer RA, Kivipelto M, Woolard N, et al. Study design and methods: U.S. study to protect brain health through lifestyle intervention to reduce risk (U.S. POINTER). Alzheimers Dement. 2024;20:769\u201382.","journal-title":"Alzheimers Dement"},{"key":"2564_CR29","doi-asserted-by":"crossref","unstructured":"Arani A, Borowski B, Felmlee J, Reid RI, Thomas DL, Gunter JL, Stables L, Buckner RL, Jung Y, Tosun D, Weiner M, Clifford R Jack J, Initiative for the ADN Design and validation of the ADNI MR protocol. Alzheimer\u2019s & Dementia 2024;20:6615.","DOI":"10.1002\/alz.14162"},{"key":"2564_CR30","doi-asserted-by":"publisher","first-page":"P104","DOI":"10.1016\/j.jalz.2017.06.2411","volume":"13","author":"JL Gunter","year":"2017","unstructured":"Gunter JL, Borowski BJ, Thostenson K, Arani A, Reid RI, Cash DM, et al. ADNI-3 Mri Protocol. Alzheimers Dement. 2017;13:P104\u2013P105.","journal-title":"Alzheimers Dement"},{"key":"2564_CR31","doi-asserted-by":"publisher","first-page":"11050","DOI":"10.1073\/pnas.200033797","volume":"97","author":"B Fischl","year":"2000","unstructured":"Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci. 2000;97:11050\u20135.","journal-title":"Proc Natl Acad Sci"},{"key":"2564_CR32","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.neuroimage.2006.01.021","volume":"31","author":"RS Desikan","year":"2006","unstructured":"Desikan RS, S\u00e9gonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. NeuroImage. 2006;31:968\u201380.","journal-title":"NeuroImage"},{"key":"2564_CR33","doi-asserted-by":"publisher","unstructured":"Ashburner J, Friston K. Voxel-Based Morphometry\u2014The Methods. 1999. 1999. https:\/\/doi.org\/10.1006\/nimg.2000.0582.","DOI":"10.1006\/nimg.2000.0582"},{"key":"2564_CR34","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1093\/cercor\/bhv062","volume":"26","author":"MJ Grothe","year":"2016","unstructured":"Grothe MJ, Heinsen H, Amaro E, Grinberg LT, Teipel SJ. for the Alzheimer\u2019s Disease Neuroimaging Initiative. Cognitive Correlates of Basal Forebrain Atrophy and Associated Cortical Hypometabolism in Mild Cognitive Impairment. Cereb Cortex. 2016;26:2411\u201326.","journal-title":"Cereb Cortex"},{"key":"2564_CR35","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.biopsych.2011.06.019","volume":"71","author":"M Grothe","year":"2012","unstructured":"Grothe M, Heinsen H, Teipel SJ. Atrophy of the cholinergic Basal forebrain over the adult age range and in early stages of Alzheimer\u2019s disease. Biol Psychiatry. 2012;71:805\u201313.","journal-title":"Biol Psychiatry"},{"key":"2564_CR36","first-page":"S344","volume":"10","author":"MJ Grothe","year":"2014","unstructured":"Grothe MJ, Ewers M, Krause B, Heinsen H, Teipel SJ. Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects. Alzheimers Dement J Alzheimers Assoc. 2014;10:S344\u2013S353.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"2564_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2019.116189","volume":"206","author":"ET Rolls","year":"2020","unstructured":"Rolls ET, Huang C-C, Lin C-P, Feng J, Joliot M. Automated anatomical labelling atlas 3. NeuroImage. 2020;206:116189.","journal-title":"NeuroImage"},{"key":"2564_CR38","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1523\/JNEUROSCI.2111-20.2020","volume":"41","author":"X Chen","year":"2021","unstructured":"Chen X, Cassady KE, Adams JN, Harrison TM, Baker SL, Jagust WJ. Regional Tau Effects on Prospective Cognitive Change in Cognitively Normal Older Adults. J Neurosci. 2021;41:366\u201375.","journal-title":"J Neurosci"},{"key":"2564_CR39","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1002\/alz.13654","volume":"20","author":"CS Fonseca","year":"2024","unstructured":"Fonseca CS, Baker SL, Dobyns L, Janabi M, Jagust WJ, Harrison TM. Tau accumulation and atrophy predict amyloid independent cognitive decline in aging. Alzheimers Dement. 2024;20:2526\u201337.","journal-title":"Alzheimers Dement"},{"key":"2564_CR40","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.neuroimage.2009.01.057","volume":"46","author":"A Joshi","year":"2009","unstructured":"Joshi A, Koeppe RA, Fessler JA. Reducing between scanner differences in multi-center PET studies. NeuroImage. 2009;46:154\u20139.","journal-title":"NeuroImage"},{"key":"2564_CR41","doi-asserted-by":"crossref","unstructured":"Landau SM, Harrison TM, Baker SL, Boswell MS, Lee J, Taggett J, Ward TJ, Chadwick T, Murphy A, DeCarli C, Schwarz CG, Vemuri P, Jack CR, Koeppe RA, Jagust WJ, U.S. POINTER Study Group and for the Alzheimer\u2019s Disease Neuroimaging Initiative. Positron emission tomography harmonization in the Alzheimer\u2019s Disease Neuroimaging Initiative: A scalable and rigorous approach to multisite amyloid and tau quantification. Alzheimers Dementia 2024; 21(1):e14378","DOI":"10.1002\/alz.14378"},{"key":"2564_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.neuroimage.2006.05.056","volume":"33","author":"J Diedrichsen","year":"2006","unstructured":"Diedrichsen J. A spatially unbiased atlas template of the human cerebellum. NeuroImage. 2006;33:127\u201338.","journal-title":"NeuroImage"},{"key":"2564_CR43","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.dib.2017.10.024","volume":"15","author":"SL Baker","year":"2017","unstructured":"Baker SL, Maass A, Jagust WJ. Considerations and code for partial volume correcting [18 F]-AV-1451 tau PET data. Data Brief. 2017;15:648\u201357.","journal-title":"Data Brief"},{"key":"2564_CR44","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack","year":"2017","unstructured":"Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement. 2017;13:205\u201316.","journal-title":"Alzheimers Dement"},{"key":"2564_CR45","doi-asserted-by":"publisher","unstructured":"Landau SM, Harrison TM, Baker SL, Boswell MS, Lee J, Taggett J, et al. Positron emission tomography harmonization in the Alzheimer\u2019s Disease Neuroimaging Initiative: A scalable and rigorous approach to multisite amyloid and tau quantification. Alzheimers Dement J Alzheimers Assoc. 2024. 19 November 2024. https:\/\/doi.org\/10.1002\/alz.14378.","DOI":"10.1002\/alz.14378"},{"key":"2564_CR46","doi-asserted-by":"crossref","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11","DOI":"10.1016\/j.jalz.2014.07.003"},{"key":"2564_CR47","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13195-021-00836-1","volume":"13","author":"SK Royse","year":"2021","unstructured":"Royse SK, Minhas DS, Lopresti BJ, Murphy A, Ward T, et al.for the lzheimer\u2019s Disease Neuroimaging Initiative Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. Alzheimers Res Ther. 2021;13:99.","journal-title":"Alzheimers Res Ther"},{"key":"2564_CR48","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/S0140-6736(26)00417-4","volume":"407","author":"G Povala","year":"2026","unstructured":"Povala G, Bellaver B, Lussier FZ, Amaral L, Bauer-Negrini G, Ferreira PCL, et al. Comparison of [18F]flortaucipir and [18F]MK6240 for the detection of tau pathology in Alzheimer\u2019s disease (HEAD): a multicentre, prospective, cross-sectional, within-participant study. Lancet. 2026;407:2217\u201326.","journal-title":"Lancet"},{"key":"2564_CR49","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.neuroimage.2017.05.058","volume":"157","author":"A Maass","year":"2017","unstructured":"Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer\u2019s disease. NeuroImage. 2017;157:448\u201363.","journal-title":"NeuroImage"},{"key":"2564_CR50","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1212\/WNL.52.7.1397","volume":"52","author":"CR Jack","year":"1999","unstructured":"Jack CR, Petersen RC, Xu YC, O\u2019Brien PC, Smith GE, Ivnik RJ, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397\u2013403.","journal-title":"Neurology"},{"key":"2564_CR51","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00415-004-0390-7","volume":"251","author":"WM van der Flier","year":"2004","unstructured":"van der Flier WM, van Buchem MA, Weverling-Rijnsburger AWE, Mutsaers ER, Bollen ELEM, Admiraal-Behloul F, et al. Memory complaints in patients with normal cognition are associated with smaller hippocampal volumes. J Neurol. 2004;251:671\u20135.","journal-title":"J Neurol"},{"key":"2564_CR52","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1212\/WNL.54.3.581","volume":"54","author":"RC Petersen","year":"2000","unstructured":"Petersen RC, Jack CR, Xu YC, Waring SC, O\u2019Brien PC, Smith GE, et al. Memory and MRI-based hippocampal volumes in aging and AD. Neurology. 2000;54:581\u20137.","journal-title":"Neurology"},{"key":"2564_CR53","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.neuropsychologia.2018.08.005","volume":"119","author":"F Lammers","year":"2018","unstructured":"Lammers F, Borchers F, Feinkohl I, Hendrikse J, Kant IMJ, Kozma P, et al. Basal forebrain cholinergic system volume is associated with general cognitive ability in the elderly. Neuropsychologia. 2018;119:145\u201356.","journal-title":"Neuropsychologia"},{"key":"2564_CR54","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.nicl.2014.11.015","volume":"7","author":"GM Kerbler","year":"2015","unstructured":"Kerbler GM, Fripp J, Rowe CC, Villemagne VL, Salvado O, Rose S, et al. Basal forebrain atrophy correlates with amyloid \u03b2 burden in Alzheimer\u2019s disease. NeuroImage Clin. 2015;7:105\u201313.","journal-title":"NeuroImage Clin"},{"key":"2564_CR55","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/jon.12921","volume":"31","author":"M Aghourian","year":"2021","unstructured":"Aghourian M, Aumont \u00c9, Grothe MJ, Soucy J-P, Rosa-Neto P, Bedard M-A. FEOBV-PET to quantify cortical cholinergic denervation in AD: Relationship to basal forebrain volumetry. J Neuroimaging. 2021;31:1077\u201381.","journal-title":"J Neuroimaging"},{"key":"2564_CR56","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/brain\/awaa012","volume":"143","author":"S Fern\u00e1ndez-Cabello","year":"2020","unstructured":"Fern\u00e1ndez-Cabello S, Kronbichler M, van Dijk KRA, Goodman JA, Nathan Spreng R, Schmitz TW. Basal forebrain volume reliably predicts the cortical spread of Alzheimer\u2019s degeneration. Brain. 2020;143:993\u20131009.","journal-title":"Brain"},{"key":"2564_CR57","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.celrep.2018.06.001","volume":"24","author":"TW Schmitz","year":"2018","unstructured":"Schmitz TW, Mur M, Aghourian M, Bedard MA, Spreng RN. Longitudinal Alzheimer\u2019s Degeneration Reflects the Spatial Topography of Cholinergic Basal Forebrain Projections. Cell Rep. 2018;24:38\u201346.","journal-title":"Cell Rep"},{"key":"2564_CR58","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.neurobiolaging.2024.03.003","volume":"139","author":"N Shafiee","year":"2024","unstructured":"Shafiee N, Fonov V, Dadar M, Spreng RN, Collins DL. Degeneration in Nucleus basalis of Meynert signals earliest stage of Alzheimer\u2019s disease progression. Neurobiol Aging. 2024;139:54\u201363.","journal-title":"Neurobiol Aging"},{"key":"2564_CR59","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00213-011-2456-4","volume":"220","author":"RA Lenz","year":"2012","unstructured":"Lenz RA, Baker JD, Locke C, Rueter LE, Mohler EG, Wesnes K, et al. The scopolamine model as a pharmacodynamic marker in early drug development. Psychopharmacology. 2012;220:97\u2013107.","journal-title":"Psychopharmacology"},{"key":"2564_CR60","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1037\/1064-1297.11.1.56","volume":"11","author":"MZ Mintzer","year":"2003","unstructured":"Mintzer MZ, Griffiths RR. Lorazepam and scopolamine: A single-dose comparison of effects on human memory and attentional processes. Exp Clin Psychopharmacol. 2003;11:56\u201372.","journal-title":"Exp Clin Psychopharmacol"},{"key":"2564_CR61","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/S0165-0173(01)00044-3","volume":"35","author":"M Sarter","year":"2001","unstructured":"Sarter M, Givens B, Bruno JP. The cognitive neuroscience of sustained attention: where top-down meets bottom-up. Brain Res Rev. 2001;35:146\u201360.","journal-title":"Brain Res Rev"},{"key":"2564_CR62","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1177\/13872877241297382","volume":"102","author":"H Suzuki","year":"2024","unstructured":"Suzuki H, Tagai K, Ono M, Shimizu H, Endo H, Matsumoto H, et al. Distinct tau pathologies in the nucleus basalis of Meynert between early-onset and late-onset Alzheimer\u2019s disease patients revealed by positron emission tomography. J Alzheimer\u2019s Dis. 2024;102:1271\u201385.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"2564_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105192","volume":"150","author":"AS Berry","year":"2023","unstructured":"Berry AS, Harrison TM. New perspectives on the basal forebrain cholinergic system in Alzheimer\u2019s disease. Neurosci Biobehav Rev. 2023;150:105192.","journal-title":"Neurosci Biobehav Rev"},{"key":"2564_CR64","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1001\/jamaneurol.2018.2505","volume":"76","author":"GS Gibbons","year":"2019","unstructured":"Gibbons GS, Lee VMY, Trojanowski JQ. Mechanisms of Cell-to-Cell Transmission of Pathological Tau. JAMA Neurol. 2019;76:101.","journal-title":"JAMA Neurol"},{"key":"2564_CR65","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/embor.2013.15","volume":"14","author":"AM Pooler","year":"2013","unstructured":"Pooler AM, Phillips EC, Lau DHW, Noble W, Hanger DP. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 2013;14:389\u201394.","journal-title":"EMBO Rep"},{"key":"2564_CR66","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/brain\/awz026","volume":"142","author":"N Franzmeier","year":"2019","unstructured":"Franzmeier N, Rubinski A, Neitzel J, Kim Y, Damm A, Na DL, et al. Functional connectivity associated with tau levels in ageing, Alzheimer\u2019s, and small vessel disease. Brain. 2019;142:1093\u2013107.","journal-title":"Brain"},{"key":"2564_CR67","doi-asserted-by":"crossref","unstructured":"Adams JN, Maass A, Harrison TM, Baker SL, Jagust WJ. Cortical tau deposition follows patterns of entorhinal functional connectivity in aging. eLife. 2019;8:e49132","DOI":"10.7554\/eLife.49132"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02564-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02564-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02564-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:03:39Z","timestamp":1790100219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02564-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":67,"alternative-id":["2564"],"URL":"https:\/\/doi.org\/10.1038\/s41386-026-02564-2","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.M.L. is on the advisory board for KeifeRX and NIH IPAT study, consults for the API\/A4 eSMARTER study, and has received speaker fees from Eisai and IMPACT-AD. W.J.J. consults for Lilly, Eisai, and Prothena. T.M.H., T.A.C., M.J.G., T.W., and S.L.B. have no competing interests to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}